StockWatch
·

Wellgistics Health, Inc. Q2 FY26 Results

WGRXQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue1.7814.1%77.2%
Total Income1.7814.1%77.2%
Expenditure9.1220.3%31.4%
PBT-18.36137.2%175.3%
Net Profit-18.36137.2%175.3%
OPM—
NPM—
EPS-7.1310085.7%6381.8%
View full financials

DataMeds AI Reports Q2 2026 Financials and Business Update

18 Aug 2026 · 18 Aug, 5:18 pm

Summary

DataMeds AI, Inc. reported second quarter 2026 financials, with revenues growing 14% to $1.779 million, exceeding management projections. The company also provided a business update highlighting significant corporate actions and strategic initiatives. Management expressed excitement about progress towards launching the Health Lives Here app with NFL Alumni Health, emphasizing the consolidation of key healthcare infrastructure for a seamless patient experience.

Key Highlights

  1. 1

    Revenues grew 14% reaching $1.779M in Q2/26, beating management projections.

  2. 2

    The company completed a 1:50 reverse stock split in May 2026 to partially address NASDAQ delisting risk.

  3. 3

    A $6.5 million new funding round was secured in June 2026 to support a corporate turnaround.

  4. 4

    The KareRx joint venture added Electronic Benefits Verification (EBV) and access to 200,000 patient lives, beginning to provide material revenue to the rebranded Corexa Pharmacy.

  5. 5

    The company expects to launch the Health Lives Here (HLH) consumer app with NFL Alumni Health (NFLAH) in September 2026, targeting patients on GLP-1 agonist medications in rural communities.

  6. 6

    The corporate name change from Wellgistics Health, Inc. to DataMeds AI, Inc. occurred in July 2026, leading to a stock symbol change from ‘WGRX’ to ‘MEDS’ on NASDAQ Capital Markets.

Management Comments

G

Gerald Commissiong

Having been in leadership now for just under three months, I am excited with the significant progress we are making towards the important milestone of launching the Health Lives Here app together with NFLAH. As we move towards this important milestone, we have successfully begun consolidating the key healthcare infrastructure needed to deliver a workflow for the patient that will result in a seamless patient experience that will allow patients to engage with their healthcare in a way that was previously not possible. We intend to engage the patient through telemedicine, a consumer app and their local independent pharmacist who will be educated on the pharmaceutical-adjunct products we provide through our relationship with Tollo Health that are intended to help mitigate drugs’ side effects and improve their effectiveness at the initial HLH app launch. As previously stated, we intend to acquire a CLIA lab that will allow us to offer direct-to-consumer testing, adding an additional layer of service for patients while allowing us to further integrate our customers’ healthcare data into their patient profiles that patients will be able to ‘opt-in’ to be fed into our EinsteinRx artificial intelligence platform to gain unique healthcare insights, including wearables data correlated with pharmacodynamic drug response. Ultimately we intend to move all of this data onto the blockchain, protected through our Datavault AI (NASDAQ: DVLT) license that provides us with patent protection on healthcare data tokenization and monetization, allowing us to provide patients with an opportunity to participate in the revenue generated through the sale of their health data.

Informational and educational content only. Not investment advice.